SCHEMBL3501242

SCHEMBL3501242

O=C(c1ccc(O)cc1F)C(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.43
CES1 P23141 2/20 0.43
CA12 O43570 4/20 0.41
CA1 P00915 4/20 0.41
CA2 P00918 4/20 0.41
CA7 P43166 4/20 0.41
CA9 Q16790 4/20 0.41
CA14 Q9ULX7 4/20 0.41
ALDH1A1 P00352 3/20 0.41
TSHR P16473 1/20 0.41
MIF P14174 1/20 0.41
MAPK1 P28482 1/20 0.39
CHRNA7 P36544 1/20 0.39
ESRRG P62508 1/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ESR1 P03372 3/20 0.37
ESR2 Q92731 2/20 0.37
ALOX5 P09917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28472548 0.85 CES2 (0.41) CES2CES1CA12CA1CA2
SCHEMBL176957 0.82 CA12 (0.43) CES2CES1CA12CA1CA2
SCHEMBL7806345 0.82 CES2 (0.63) CES2CES1ALDH1A1HTT
SCHEMBL11015067 0.79 CES2 (0.48) CES2CES1CA12CA1CA2
SCHEMBL11916367 0.78 HSP90AB1 (0.43) CES2CES1CA12CA1CA2
SCHEMBL3816558 0.77 CES2 (0.46) CES2CES1CA12CA1CA2
SCHEMBL311907 0.77 CA12 (0.61) CES2CES1CA12CA1CA2
SCHEMBL29799863 0.75 MAOB (0.50) CES2CES1CA12CA1CA2
SCHEMBL3810726 0.75 CES2 (0.45) CES2CES1CA12CA1CA2
Hydrochloric Acid SCHEMBL9627416 0.75 CA12 (0.59) CES2CES1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193228-B2 Substituted imidazole as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. (US) 2012-06-05 US disclosed
US-20100022598-A1 Substituted inmidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME LLC 2010-01-28 US disclosed
EP-2091937-A2 SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS Merck & Co., Inc. (US) 2009-08-26 EP disclosed
WO-2008051406-A2 SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS MERCK & CO., INC. (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022598-A1 Substituted inmidazoles as bombesin receptor subtype-3 modulators BRS3, INSR, INSRR CES2 1114/4885CES1 744/4885CA12 4360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.